224 related articles for article (PubMed ID: 26104661)
1. Antileukemia multifunctionality of CD4(+) T cells genetically engineered by HLA class I-restricted and WT1-specific T-cell receptor gene transfer.
Fujiwara H; Ochi T; Ochi F; Miyazaki Y; Asai H; Narita M; Okamoto S; Mineno J; Kuzushima K; Shiku H; Yasukawa M
Leukemia; 2015 Dec; 29(12):2393-401. PubMed ID: 26104661
[TBL] [Abstract][Full Text] [Related]
2. Novel adoptive T-cell immunotherapy using a WT1-specific TCR vector encoding silencers for endogenous TCRs shows marked antileukemia reactivity and safety.
Ochi T; Fujiwara H; Okamoto S; An J; Nagai K; Shirakata T; Mineno J; Kuzushima K; Shiku H; Yasukawa M
Blood; 2011 Aug; 118(6):1495-503. PubMed ID: 21673345
[TBL] [Abstract][Full Text] [Related]
3. HLA-DPB1*05: 01-restricted WT1332-specific TCR-transduced CD4+ T lymphocytes display a helper activity for WT1-specific CTL induction and a cytotoxicity against leukemia cells.
Lin Y; Fujiki F; Katsuhara A; Oka Y; Tsuboi A; Aoyama N; Tanii S; Nakajima H; Tatsumi N; Morimoto S; Tamanaka T; Tachino S; Hosen N; Nishida S; Oji Y; Kumanogoh A; Sugiyama H
J Immunother; 2013 Apr; 36(3):159-70. PubMed ID: 23502763
[TBL] [Abstract][Full Text] [Related]
4. Transduction of a novel HLA-DRB1*04:05-restricted, WT1-specific TCR gene into human CD4+ T cells confers killing activity against human leukemia cells.
Katsuhara A; Fujiki F; Aoyama N; Tanii S; Morimoto S; Oka Y; Tsuboi A; Nakajima H; Kondo K; Tatsumi N; Nakata J; Nakae Y; Takashima S; Nishida S; Hosen N; Sogo S; Oji Y; Sugiyama H
Anticancer Res; 2015 Mar; 35(3):1251-61. PubMed ID: 25750272
[TBL] [Abstract][Full Text] [Related]
5. Peptide epitopes from the Wilms' tumor 1 oncoprotein stimulate CD4+ and CD8+ T cells that recognize and kill human malignant mesothelioma tumor cells.
May RJ; Dao T; Pinilla-Ibarz J; Korontsvit T; Zakhaleva V; Zhang RH; Maslak P; Scheinberg DA
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4547-55. PubMed ID: 17671141
[TBL] [Abstract][Full Text] [Related]
6. Generation of tumor-specific, HLA class I-restricted human Th1 and Tc1 cells by cell engineering with tumor peptide-specific T-cell receptor genes.
Tsuji T; Yasukawa M; Matsuzaki J; Ohkuri T; Chamoto K; Wakita D; Azuma T; Niiya H; Miyoshi H; Kuzushima K; Oka Y; Sugiyama H; Ikeda H; Nishimura T
Blood; 2005 Jul; 106(2):470-6. PubMed ID: 15790789
[TBL] [Abstract][Full Text] [Related]
7. Direct recognition and lysis of leukemia cells by WT1-specific CD4+ T lymphocytes in an HLA class II-restricted manner.
Guo Y; Niiya H; Azuma T; Uchida N; Yakushijin Y; Sakai I; Hato T; Takahashi M; Senju S; Nishimura Y; Yasukawa M
Blood; 2005 Aug; 106(4):1415-8. PubMed ID: 15845894
[TBL] [Abstract][Full Text] [Related]
8. Identification and characterization of a WT1 (Wilms Tumor Gene) protein-derived HLA-DRB1*0405-restricted 16-mer helper peptide that promotes the induction and activation of WT1-specific cytotoxic T lymphocytes.
Fujiki F; Oka Y; Tsuboi A; Kawakami M; Kawakatsu M; Nakajima H; Elisseeva OA; Harada Y; Ito K; Li Z; Tatsumi N; Sakaguchi N; Fujioka T; Masuda T; Yasukawa M; Udaka K; Kawase I; Oji Y; Sugiyama H
J Immunother; 2007 Apr; 30(3):282-93. PubMed ID: 17414319
[TBL] [Abstract][Full Text] [Related]
9. [Immunotherapy for leukemia cells by using cytotoxic T lymphocyte specifically against WT1-derived peptide: an experimental study in vitro].
Gu WY; Cao XS; Qiu GQ; Chen ZX; Sheng LX; Xie XB; He J; Cen JN; Shen HL
Zhonghua Yi Xue Za Zhi; 2005 Dec; 85(49):3475-80. PubMed ID: 16686063
[TBL] [Abstract][Full Text] [Related]
10. Recognition of a natural WT1 epitope by a modified WT1 peptide-specific T-cell receptor.
Tamanaka T; Oka Y; Fujiki F; Tsuboi A; Katsuhara A; Nakajima H; Hosen N; Nishida S; Lin YH; Tachino S; Akatsuka Y; Kuzushima K; Oji Y; Kumanogoh A; Sugiyama H
Anticancer Res; 2012 Dec; 32(12):5201-9. PubMed ID: 23225417
[TBL] [Abstract][Full Text] [Related]
11. Generation of donor-derived Wilms tumor antigen 1-specific cytotoxic T lymphocytes with potent anti-leukemia activity for somatic cell therapy in children given haploidentical stem cell transplantation: a feasibility pre-clinical study.
Ferulli F; Tanzi M; Turin I; Montini E; Rosti V; Acquafredda G; Lisini D; Compagno F; Boghen S; Licari A; Marseglia G; Zecca M; Montagna D
Cytotherapy; 2019 Sep; 21(9):958-972. PubMed ID: 31279696
[TBL] [Abstract][Full Text] [Related]
12. A WT1 protein-derived, naturally processed 16-mer peptide, WT1(332), is a promiscuous helper peptide for induction of WT1-specific Th1-type CD4(+) T cells.
Fujiki F; Oka Y; Kawakatsu M; Tsuboi A; Nakajima H; Elisseeva OA; Harada Y; Li Z; Tatsumi N; Kamino E; Shirakata T; Nishida S; Taniguchi Y; Kawase I; Oji Y; Sugiyama H
Microbiol Immunol; 2008 Dec; 52(12):591-600. PubMed ID: 19120973
[TBL] [Abstract][Full Text] [Related]
13. [Cytotoxicity of T cells transduced with WT1 peptide-specific T-cell receptor gene against human lung cancer cells in vitro].
An J; Cai SW; Li Y; Zhang J
Nan Fang Yi Ke Da Xue Xue Bao; 2014 Aug; 34(9):1319-23. PubMed ID: 25263367
[TBL] [Abstract][Full Text] [Related]
14. The Wilms' tumor antigen is a novel target for human CD4+ regulatory T cells: implications for immunotherapy.
Lehe C; Ghebeh H; Al-Sulaiman A; Al Qudaihi G; Al-Hussein K; Almohareb F; Chaudhri N; Alsharif F; Al-Zahrani H; Tbakhi A; Aljurf M; Dermime S
Cancer Res; 2008 Aug; 68(15):6350-9. PubMed ID: 18676860
[TBL] [Abstract][Full Text] [Related]
15. Redirecting human CD4+ T lymphocytes to the MHC class I-restricted melanoma antigen MAGE-A1 by TCR alphabeta gene transfer requires CD8alpha.
Willemsen R; Ronteltap C; Heuveling M; Debets R; Bolhuis R
Gene Ther; 2005 Jan; 12(2):140-6. PubMed ID: 15496961
[TBL] [Abstract][Full Text] [Related]
16. Simultaneous in vitro generation of CD8 and CD4 T cells specific to three universal tumor associated antigens of WT1, survivin and TERT and adoptive T cell transfer for the treatment of acute myeloid leukemia.
Sohn HJ; Lee JY; Lee HJ; Sohn DH; Cho HI; Kim HJ; Kim TG
Oncotarget; 2017 Jul; 8(27):44059-44072. PubMed ID: 28477011
[TBL] [Abstract][Full Text] [Related]
17. WT1 peptide-specific T cells generated from peripheral blood of healthy donors: possible implications for adoptive immunotherapy after allogeneic stem cell transplantation.
Weber G; Karbach J; Kuçi S; Kreyenberg H; Willasch A; Koscielniak E; Tonn T; Klingebiel T; Wels WS; Jäger E; Bader P
Leukemia; 2009 Sep; 23(9):1634-42. PubMed ID: 19357702
[TBL] [Abstract][Full Text] [Related]
18. PRAME peptide-specific CD8
Matko S; Manderla J; Bonsack M; Schmitz M; Bornhauser M; Tonn T; Odendahl M
Eur J Immunol; 2018 Aug; 48(8):1400-1411. PubMed ID: 29738081
[TBL] [Abstract][Full Text] [Related]
19. Impact of mature dendritic cells pulsed with a novel WT1 helper peptide on the induction of HLA‑A2‑restricted WT1‑reactive CD8+ T cells.
Kan S; Bito T; Shimabuku M; Taguchi J; Ohkusa T; Shimodaira S; Sugiyama H; Koido S
Int J Oncol; 2020 Oct; 57(4):1047-1056. PubMed ID: 32945369
[TBL] [Abstract][Full Text] [Related]
20. Analysis of the functional WT1-specific T-cell repertoire in healthy donors reveals a discrepancy between CD4(+) and CD8(+) memory formation.
Schmied S; Gostick E; Price DA; Abken H; Assenmacher M; Richter A
Immunology; 2015 Aug; 145(4):558-69. PubMed ID: 25882672
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
